Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 2 3Phase 3 2Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 3Leukemia, Myeloid, Chronic-Phase 2Gastrointestinal Stromal Tumors 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Blast Crisis 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 72Cytarabine 46fludarabine phosphate 45fludarabine 42Vincristine 29Filgrastim 27Peripheral Blood Stem Cell Transplantation 25Methotrexate 25Etoposide 24Dexamethasone 23Melphalan 21Rituximab 20Doxorubicin 19Clofarabine 19Tacrolimus 17Mycophenolic Acid 17Dasatinib 16Bortezomib 15Whole-Body Irradiation 14Vorinostat 14pegaspargase 13Cyclosporine 13Calcium Dobesilate 13Busulfan 13Antilymphocyte Serum 12tanespimycin 10Topotecan 10Stem Cell Transplantation 10Specimen Handling 10Sirolimus 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × nilotinib × Clear all
NCT01077544 2020-12-29

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 1 Completed
15 enrolled 20 charts 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡